AlphaValue/Baader Europe upgraded AstraZeneca from 'reduce' to 'add' on Tuesday, while lowering its price target from 118.05 pounds sterling to 116.08 pounds.
AstraZeneca partners with SOPHiA GENETICS to enhance the MSK/ACCESS liquid biopsy test, using the DDM Platform to boost biomarker discovery and precision medicine for biopharma clients.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.